Friday, March 21, 2008

Little Orphan Ending

...At any rate, the NEJM article describes four bills as having been introduced in the U.S. Congress in 2007 to expedite approval of follow-on protein products.  None reached the floor.  The article cheerfully concludes "despite failures of the bills... [they] collectively represent important first steps that should help stimulate further discourse... and signal an end to the de facto permanent patent that a recombinant protein therapeutic currently enjoys."  In the meantime, its a hard knock life for persons with ultra-rare disorders.   (photo credit: dishevld 2007)

No comments: